Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.58 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.58 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.58 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.55 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820794 | 1.00 | NT5E (0.67) | NT5EPOLBENPP1P2RY1P2RY6 | |
| SCHEMBL17117823 | 1.00 | NT5E (0.67) | NT5EPOLBENPP1P2RY1P2RY6 | |
| SCHEMBL12932286 | 1.00 | NT5E (0.67) | NT5EPOLBENPP1P2RY1P2RY6 | |
| SCHEMBL29400356 | 1.00 | NT5E (0.67) | NT5EPOLBENPP1P2RY1P2RY6 | |
| SCHEMBL15573313 | 0.93 | NT5E (0.64) | NT5EPOLBENPP1P2RY1P2RY6 | |
| SCHEMBL29642033 | 0.93 | NT5E (0.64) | NT5EPOLBENPP1P2RY1P2RY6 | |
| SCHEMBL3207372 | 0.91 | NT5E (0.72) | NT5EPOLBENPP1P2RY1P2RY11 | |
| SCHEMBL29808596 | 0.91 | NT5E (0.72) | NT5EPOLBENPP1P2RY1P2RY11 | |
| SCHEMBL17117807 | 0.91 | NT5E (0.72) | NT5EPOLBENPP1P2RY1P2RY11 | |
| 2-Chlorodeoxyadenosine Triphosphate SCHEMBL1064487 | 0.91 | NT5E (0.78) | NT5EPOLBENPP1P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250210148-A1 | METHOD OF PRODUCING DATA-ENCODED NUCLEIC ACID AND NUCLEIC ACID PRODUCED BY THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| US-20240182874-A1 | NOVEL FAMILY OF DNA POLYMERASES ACCEPTING 2-AMINOADENINE AND REJECTING ADENINE IN THEIR SUBSTRATES | THE EUROPEAN SYNDICATE OF SYNTHETIC SCIENTISTS AND IND (FR) | 2024-06-06 | — | — | US | claimed |
| EP-4323511-A1 | NOVEL FAMILY OF DNA POLYMERASES ACCEPTING 2-AMINOADENINE AND REJECTING ADENINE IN THEIR SUBSTRATES | The European Syndicate of Synthetic Scientists and Industrialists (FR) | 2024-02-21 | — | — | EP | claimed |
| US-11427864-B2 | Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients | EXOSOME DIAGNOSTICS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| EP-3548635-B1 | METHODS TO DETECT MUTATIONS IN PLASMA USING EXOSOMAL RNA AND CELL FREE DNA FROM NON-SMALL CELL LUNG CANCER PATIENTS | EXOSOME DIAGNOSTICS INC (US) | 2021-04-28 | — | — | EP | claimed |
| EP-3548635-A1 | METHODS AND COMPOSITIONS TO DETECT MUTATIONS IN PLASMA USING EXOSOMAL RNA AND CELL FREE DNA FROM NON-SMALL CELL LUNG CANCER PATIENTS | Exosome Diagnostics, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| WO-2018102162-A1 | METHODS AND COMPOSITIONS TO DETECT MUTATIONS IN PLASMA USING EXOSOMAL RNA AND CELL FREE DNA FROM NON-SMALL CELL LUNG CANCER PATIENTS | EXOSOME DIAGNOSTICS, INC. (US) | 2018-06-07 | — | — | WO | claimed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| EP-2451980-B1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES (US) | 2014-05-21 | — | — | EP | claimed |
| US-8728725-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES (US) | 2014-05-20 | — | — | US | claimed |
| EP-2451980-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TriLink BioTechnologies (US) | 2012-05-16 | — | — | EP | claimed |
| US-20110008788-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TriLink Bio Technologies | 2011-01-13 | — | — | US | claimed |
| WO-2011005762-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES (US) | 2011-01-13 | — | — | WO | claimed |
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20050032055-A1 | Methods of making nucleic acid molecules with reduced secondary structure | SAMPSON JEFFREY R (US) | 2005-02-10 | — | — | US | claimed |
| US-20050032053-A1 | Nucleic acid molecules with reduced secondary structure | SAMPSON JEFFREY R (US) | 2005-02-10 | — | — | US | claimed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
| EP-1072679-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies Inc. (US) | 2001-01-31 | — | — | EP | claimed |
| US-20260092310-A1 | CAS12A COMPOSITIONS AND METHODS | NEW ENGLAND BIOLABS, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-1072679-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies Inc. (US) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092310-A1 | CAS12A COMPOSITIONS AND METHODS | RNASEL, RBM12, NT5C2 | NT5E 18/4885POLB 112/4885ENPP1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.